🚀 VC round data is live in beta, check it out!
Surrozen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Surrozen and similar public comparables like SIGA Technologies, Celon Pharma, Duopharma Biotech, Zentalis Pharma and more.
Surrozen Overview
About Surrozen
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Founded
2015
HQ
Employees
41
Website
Sectors
Financials (LTM)
EV
$233M
Surrozen Financials
Surrozen reported last 12-month revenue of $4M.
In the same LTM period, Surrozen generated had net loss of ($190M).
Revenue (LTM)
Surrozen P&L
In the most recent fiscal year, Surrozen reported revenue of $3M and EBITDA of ($42M).
Surrozen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | $3M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($42M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1195%) | XXX | XXX | XXX |
| EBIT Margin | (1016%) | XXX | (1211%) | XXX | XXX | XXX |
| Net Profit | ($190M) | XXX | ($242M) | XXX | XXX | XXX |
| Net Margin | (4229%) | XXX | (6961%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Surrozen Stock Performance
Surrozen has current market cap of $315M, and enterprise value of $233M.
Market Cap Evolution
Surrozen's stock price is $27.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $233M | $315M | 5.9% | XXX | XXX | XXX | $-21.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSurrozen Valuation Multiples
Surrozen trades at 51.7x EV/Revenue multiple, and (5.6x) EV/EBITDA.
EV / Revenue (LTM)
Surrozen Financial Valuation Multiples
As of April 11, 2026, Surrozen has market cap of $315M and EV of $233M.
Equity research analysts estimate Surrozen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Surrozen has a P/E ratio of (1.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $315M | XXX | $315M | XXX | XXX | XXX |
| EV (current) | $233M | XXX | $233M | XXX | XXX | XXX |
| EV/Revenue | 51.7x | XXX | 66.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.6x) | XXX | XXX | XXX |
| EV/EBIT | (5.1x) | XXX | (5.5x) | XXX | XXX | XXX |
| P/E | (1.7x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Surrozen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Surrozen Margins & Growth Rates
Surrozen's revenue in the last 12 month grew by 23%.
Surrozen's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.1M for the same period.
Surrozen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 107% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1195%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 72% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 380% | XXX | 466% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 735% | XXX | 845% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1311% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Surrozen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SIGA Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Celon Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Duopharma Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentalis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinuvel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Surrozen M&A Activity
Surrozen acquired XXX companies to date.
Last acquisition by Surrozen was on XXXXXXXX, XXXXX. Surrozen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Surrozen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSurrozen Investment Activity
Surrozen invested in XXX companies to date.
Surrozen made its latest investment on XXXXXXXX, XXXXX. Surrozen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Surrozen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Surrozen
| When was Surrozen founded? | Surrozen was founded in 2015. |
| Where is Surrozen headquartered? | Surrozen is headquartered in United States. |
| How many employees does Surrozen have? | As of today, Surrozen has over 41 employees. |
| Who is the CEO of Surrozen? | Surrozen's CEO is Craig C. Parker. |
| Is Surrozen publicly listed? | Yes, Surrozen is a public company listed on Nasdaq. |
| What is the stock symbol of Surrozen? | Surrozen trades under SRZN ticker. |
| When did Surrozen go public? | Surrozen went public in 2021. |
| Who are competitors of Surrozen? | Surrozen main competitors are SIGA Technologies, Celon Pharma, Duopharma Biotech, Zentalis Pharma. |
| What is the current market cap of Surrozen? | Surrozen's current market cap is $315M. |
| What is the current revenue of Surrozen? | Surrozen's last 12 months revenue is $4M. |
| What is the current revenue growth of Surrozen? | Surrozen revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Surrozen? | Current revenue multiple of Surrozen is 51.7x. |
| Is Surrozen profitable? | No, Surrozen is not profitable. |
| What is the current net income of Surrozen? | Surrozen's last 12 months net income is ($190M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.